In short: measure AI in pharma commercial in the only unit the business actually rewards, moved prescriptions attributed to specific brands and territories, read through SMSRC and IQVIA with a 60 to 90-day lag accepted up front. Activity and adoption metrics are easy to collect and prove nothing. The honest ROI story is slower, smaller in its claims, and far more durable in a board review.
Every AI vendor and every internal champion wants to show ROI fast, so they reach for the metrics that move fast: usage, time saved, calls logged, decks drafted. Those numbers go up reliably and tell you almost nothing about whether the brand moved. The leaders who keep their AI budget through the second year are the ones who refused the easy metric and measured the hard one. This is how they do it.
The short answer
Pick the output the business already measures the commercial function on, prescription movement and market share, and measure the AI workload against that, accepting the lag and the attribution difficulty as part of the deal rather than designing them away. Everything faster than that is an input metric, useful for operations and useless as proof of value. The discipline that makes the slow number credible is the with-and-without comparison: the same territories, with the workload and without it, read through the same source.
Why ROI here is genuinely hard
It is worth saying plainly that the difficulty is real, not an excuse. Three things make commercial AI ROI hard in Indian pharma specifically.
The output is lagged. A change in how a Territory Manager's call plan is built shows up as moved prescriptions one to three cycles later, read through SMSRC Rx data and IQVIA secondary that themselves arrive monthly, with a lag. You cannot see next week whether it worked.
The output is contested. Prescription movement in a territory has many parents: the call plan, a Brand Manager promotion, a chemist incentive, a competitor stock-out, a regional market shift, doctor turnover. Attributing the movement to the AI workload rather than to one of those is the actual analytical problem, and it is the territory-level attribution problem in disguise.
The output runs through someone else's data. The number that proves you moved the market is IQVIA's, not yours, and it measures something subtly different from your own secondary. Proving ROI means reconciling against a dataset you do not control, which is the same plumbing problem that decides whether your data is ready in the first place.
The wrong unit: activity and adoption
The seductive metrics are the ones a dashboard can show this week. Daily active users of the tool. Hours saved drafting brand-review decks. Calls logged. Percentage of Territory Managers who opened the recommendation. Every one of these is an input, and every one of them can be green while the brand's market share falls in exactly the territories the tool was meant to help.
An MR can hit her coverage targets and her call quotas and watch her brand's IQVIA share decline, because the doctors who switched were not the ones she was prioritising. A tool can be used daily and move nothing. Adoption is necessary, it is not proof; a workload measured only on adoption is a workload that will be cut the first time the board asks what it did to the number.
The right unit: moved prescriptions, with a lag
The unit that survives scrutiny is prescription movement, attributed to the specific brands the system was meant to help, in the specific territories it was meant to help, read through SMSRC Rx and IQVIA secondary, with a 60 to 90-day lag written into the measurement plan from day one.
Writing the lag in up front is the part teams skip and regret. If you promise the board a number in six weeks, you will be forced back to the activity metrics to have something to show, and you will have quietly substituted activity for productivity again. If you tell the board at the start that the honest read lands in the second cycle, you buy the time to measure the real thing, and you set the expectation that protects the workload through the lag.
The with-and-without discipline
A raw before-and-after is not evidence; the market moved for a dozen reasons over those months. The discipline that turns prescription movement into attributable ROI is the comparison a Brand Manager can defend: the same brand, in matched territories, with the workload running and without it, read off the same source, over the same period. Where you can hold a set of comparable territories out, hold them out. Where you cannot, compare against the territory's own pre-period trend and against matched territories that did not get the intervention.
This is not academic rigour for its own sake. It is the difference between a number the board believes and a number the board's analyst can puncture in one question. The workload that can show its effect with-and-without, traceable to a primary, secondary, IQVIA, or SMSRC source, is the workload that keeps its budget. The one that shows a suggestive before-and-after does not.
What to put in front of your board
A defensible board slide for a commercial AI workload has four things on it. The output metric, in prescriptions or share, for the brands and territories in scope. The comparison that isolates the workload's effect, with-and-without or against matched controls. The lag, stated, so nobody mistakes "too early to tell" for "it failed." And the trace, the assurance that every number on the slide goes back to a named source the analyst can check.
What is deliberately not on that slide: hours saved, seats activated, decks drafted. Those go in an operations review, where they belong. They are not the proof of value, and presenting them as proof is the fastest way to teach a sceptical CFO that AI ROI in pharma is hand-waving.
Why this belongs in the consortium
Nobody publishes their real ROI methodology for commercial AI, because it is competitive and because the honest version is unglamorous. So the only way to calibrate yours is to compare notes with a peer who has presented one to their own board and survived the questions, and with the engineer who built the attribution that held up. How long a lag is honest, which control design a CFO accepts, how to talk about a contested number without overclaiming: that is tacit knowledge, and it transfers in a room, not a webinar.
That is what AI for Pharma is convened to host: commercial leaders and the people building for them, working through the measurement problem that decides whether AI keeps its budget. If "what is the ROI" is the question your board is asking, apply.